Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Eloxx Pharmaceuticals, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

Omitted as we are a “smaller reporting company”, as defined in Item 10(f)(1) of SEC Regulation S-K.